US 9522185
Human antibodies to GFR α3 and methods of treating pain associated with osteoarthritis or bone cancer
granted A61KA61K2039/505A61K39/001103
Quick answer
US patent 9522185 (Human antibodies to GFR α3 and methods of treating pain associated with osteoarthritis or bone cancer) held by REGENERON PHARMACEUTICALS, INC. expires Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- REGENERON PHARMACEUTICALS, INC.
- Grant date
- Tue Dec 20 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 15 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 9
- CPC classes
- A61K, A61K2039/505, A61K39/001103, A61K39/39533, A61K39/39541